| Literature DB >> 33678249 |
Gustavo de Alencastro1, Francesco Puzzo1, Mara Pavel-Dinu2, Feijie Zhang1, Sirika Pillay3, Karim Majzoub3, Matthew Tiffany1, Hagoon Jang1, Adam Sheikali2, M Kyle Cromer2, Ruhikanta Meetei4, Jan E Carette3, Matthew H Porteus2, Katja Pekrun1, Mark A Kay5.
Abstract
Recombinant adeno-associated virus (rAAV) vectors have the unique property of being able to perform genomic targeted integration (TI) without inducing a double-strand break (DSB). In order to improve our understanding of the mechanism behind TI mediated by AAV and improve its efficiency, we performed an unbiased genetic screen in human cells using a promoterless AAV-homologous recombination (AAV-HR) vector system. We identified that the inhibition of the Fanconi anemia complementation group M (FANCM) protein enhanced AAV-HR-mediated TI efficiencies in different cultured human cells by ∼6- to 9-fold. The combined knockdown of the FANCM and two proteins also associated with the FANCM complex, RecQ-mediated genome instability 1 (RMI1) and Bloom DNA helicase (BLM) from the BLM-topoisomerase IIIα (TOP3A)-RMI (BTR) dissolvase complex (RMI1, having also been identified in our screen), led to the enhancement of AAV-HR-mediated TI up to ∼17 times. AAV-HR-mediated TI in the presence of a nuclease (CRISPR-Cas9) was also increased by ∼1.5- to 2-fold in FANCM and RMI1 knockout cells, respectively. Furthermore, knockdown of FANCM in human CD34+ hematopoietic stem and progenitor cells (HSPCs) increased AAV-HR-mediated TI by ∼3.5-fold. This study expands our knowledge on the mechanisms related to AAV-mediated TI, and it highlights new pathways that might be manipulated for future improvements in AAV-HR-mediated TI.Entities:
Keywords: AAV; AAV-HR; CRISPR/Cas9; GeneRide; genome editing; homologous recombination; nuclease-free; targeted integration
Mesh:
Substances:
Year: 2020 PMID: 33678249 PMCID: PMC7934449 DOI: 10.1016/j.ymthe.2020.10.020
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454